'%2F%3E%3Cpath%20d%3D'M6.5%2025%2016%207%2025.5%2025'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.8'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'16'%20cy%3D'19'%20r%3D'3.2'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Walpar Nutritions Limited
WALPAR (NSE) · ISIN INE0G2G01015 · Pharmaceuticals · listed 2021
Not on any surveillance list
Next: Board meeting: financial results on 5 November 2026.
Quarterly results
No quarterly results stored for this company yet.
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹16.98 cr | ₹1.91 cr | ₹39.92 cr |
| 30 Sep 2025 standalone | ₹16.01 cr | ₹0.21 cr | ₹35.07 cr |
| 31 Mar 2025 standalone | ₹15.02 cr | ₹0 cr | ₹30.92 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 68.99% | 0.00% | 0.00% | 31.01% |
Latest filings
- Annual Report FY2025-26 (New) 29 August 2026 · NSE
- Walpar Nutritions Limited has informed the Exchange regarding Outcome of Board Meeting held on August 29, 2026. 29 August 2026 · NSE
- Walpar Nutritions Limited has informed the Exchange regarding Outcome of Board Meeting held on August 29, 2026. 29 August 2026 · NSE
- Walpar Nutritions Limited has informed the Exchange regarding Outcome of Board Meeting held on August 29, 2026. 29 August 2026 · NSE
- Kalpesh Ladhawala has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 12 June 2026 · NSE
Other companies in Pharmaceuticals
- Sun Pharmaceutical Industries Limited
- Lupin Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Mankind Pharma Limited
- Aurobindo Pharma Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 29 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.